## NEURO**Metrix**®

## NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

April 19, 2022

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26, 2022 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 5754338. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at <u>www.NeuroMetrix.com</u> under the "Investor Relations" tab.

A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 5754338. The replay will be available for one week after the conference call.

## About NeuroMetrix

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck<sup>®</sup> is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE<sup>®</sup> is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell<sup>®</sup> is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit <u>www.NeuroMetrix.com</u>.

NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.



Source: NeuroMetrix, Inc.